Labopharm Reports Results for Third Quarter F...(------------------------------------- ...),Health

Date:11/6/2009

------------------------------------- Net loss for the period (6,904) (6,017) (19,752) (26,013) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net loss per share - basic and diluted (0.12) (0.11) (0.35) (0.46) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of common shares outstanding 57,388,302 56,824,106 57,020,122 56,821,325 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Labopharm Inc. INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) For the three months ended: For the nine months ended: September September September September 30, 30, 30, 30, 2009 2008 2009 2008 (thousands of Canadian (Restated) (Restated) dollars) $ $ $ $ ------------------------------------------------------------------------- OPERATING ACTIVITIES Net loss for the period (6,904) (6,017) (19,752) (26,013) Items not affecting cash: Depreciation of property, plant and equipment 396 471 1,229 1,386 Amortization of intangible assets 46 30 129 90 Amortization of premiums and discounts on marketable securities 36 6 90
'/>"/>

SOURCE Labopharm Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine news :

1. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
2. Labopharms response for novel trazodone formulation accepted by FDA as complete - Designated as Class 2 resubmission
3. Labopharm submits response to FDA for novel antidepressant
4. Labopharm Reports Results for Second Quarter Fiscal 2009
5. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
6. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
7. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
8. Labopharm amends debt facility agreement with Hercules
9. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
10. Labopharm Reports Results for First Quarter Fiscal 2009
11. Labopharm announces details for first quarter results conference call and annual meeting